Pancreatic Cancer Awareness
Up to 1 in 10 people with pancreatic cancer have a hereditary predisposition
Pancreatic cancer is the 15th most common cancer worldwide, but it has …Read More
The number of detected skin cancer cases is growing with worrying rates. According to the US National Foundation for Cancer Research (NFCR), over the past three decades, more people have been diagnosed with a form of skin cancer than all other cancers together.
Melanoma is a type of skin cancer. While it is less common than other skin cancer types ― as it only accounts for 1% of skin cancers ― it causes the majority of skin cancer deaths. This is because of its ability to spread to other organs and parts of the body (metastasize) very quickly if not detected and treated early.
Melanoma starts in the melanocytes, which are skin cells found in the upper layer of our skin. These cells produce the melanin pigment that determines the skin’s color and protects the skin from the ultraviolet (UV) radiation emitted by the sun.
According to the American Cancer Society’s estimations in the USA, over 200,000 melanoma cases will be diagnosed in 2021. About half of these new melanomas will be noninvasive and confined to the top skin, and the rest of the cases will be invasive and could metastasize. Nearly 7,180 people in the USA are expected to die of melanoma by the end of 2021.
The first and most common sign of melanoma is a new mole on the skin – which happens in up to 80% of the cases – or a change in the appearance of an existing one. This may happen anywhere on the body, but the most commonly affected areas in women are the legs and in men are the back and chest, which are the areas most exposed to the sun. Normal moles usually have round or oval shape with a smooth edge. In most cases of melanoma, moles have an irregular shape and more than one color. Other signs to look out for melanoma are the mole’s growth and whether it is bleeding, itchy or sore.
The ABCDE Rule is an easy-to-remember system which outlines the warning signs of melanoma:
A is for Asymmetry: Most melanomas are asymmetrical.
B is for Border: The edges are irregular and uneven.
C is for Color: The color is not the same all over and may include different shades of brown or black, or sometimes even pink, red, white, or blue.
D is for Diameter: Melanomas may have bigger diameter.
E is for Evolving: The mole is changing in size, shape, or color.
If any of the above signs are noticed, a healthcare provider must be immediately consulted to determine whether a mole or growth may be cancerous. Detecting melanoma at an early stage is crucial and makes a significant difference. If detected early – when the cancer is on the surface of the skin – melanoma has exceptional prognosis with a 5-year survival rate of 99%. The survival rate drops to 66% if the disease reaches the lymph nodes, and 27% if it has metastasized to distant organs.
In most cases, a questionable mole is usually surgically removed and sent for a biopsy so it can be examined thoroughly. If the mole is diagnosed as cancerous, and the type of melanoma is classified, the next important step is the identification of the disease stage for treatment determination. This may require additional tests such as sentinel lymph node biopsy, PET and CT scans, MRIs and blood tests. Several elements define the stage of melanoma such as how far the melanoma has grown into the skin, and if it has spread. A lower stage number means less progression of the disease.
Certain factors can increase the risk of developing melanoma. The most important risk factor is the exposure to ultraviolet (UV) radiation light. The sun is the main source of this light, but tanning beds and sun lamps are also potential sources. Having many moles, fair skin or freckles may also raise the risk as these individuals are more sensitive to sunlight. Racial identity may also play a role, as melanoma is about 20 times more frequent in Caucasians than Africans. The risk of developing melanoma also rises when having a weakened immune system as a result of medical treatments or conditions. Melanoma is more likely to occur in older people rather than young people; the average age at time of melanoma diagnosis is 65 years. Also, men have a higher rate of melanoma than women.
Gene mutations (changes) are also important risk factors for melanoma skin cancer. Mutations can be either acquired mutations that are caused by environmental factors, or hereditary mutations that exist in a person from birth and can be inherited from a parent. Having certain hereditary mutations raise the risk of developing melanoma. As hereditary mutations cluster in families, having a first-degree relative with melanoma may mean that more people in the family could also have a hereditary mutation that increases their risk of developing cancer. Overall, about 10% of newly diagnosed melanoma patients have a family history of the disease. The risk is greater for individuals if several members on one side of the family were diagnosed with melanoma, if a family member had more than one melanoma or had both melanoma and pancreatic cancer. In these cases, genetic testing can be beneficial as it can identify whether a mutation exists, and what risk factors could be avoided to reduce the risk of cancer developing in the future. Additionally, if an individual had a melanoma in the past, then that person has a greater risk of developing melanoma again in the future. Lastly, a rare inherited condition called Xeroderma pigmentosum (XP) elevates the risk of developing melanomas and other skin cancers at a young age.
When diagnosed at an early stage, surgery is the main treatment for melanoma. If it is not diagnosed until it has progressed, treatment may include immunotherapy, chemotherapy, radiation therapy and targeted therapy. A team of healthcare providers will recommend the best treatment option for each patient depending on the stage of melanoma.
In the past decade, medicines that are targeted towards specific mutations, such as the acquired mutation in the BRAF gene, have been successfully used to slow or stop cancer cells from growing. This explains why genetic testing for identifying the mutations responsible for melanoma, whether acquired or hereditary, can be beneficial. With the help of modern technologies, scientists are now able to develop vaccines for melanoma. These are currently only given as part of clinical trials, but in the future will be a novel and effective treatment option for melanoma cancer patients. The vaccine’s design is personalized for each patient as it is based on the genetic and molecular information obtained from the skin removed through a biopsy.
There is no secure path for melanoma skin cancer prevention. Certain risk factors, like family history, cannot be controlled. For individuals who have a family history of melanoma, genetic tests for specific gene mutations associated with melanoma can determine whether someone has an increased risk of developing this disease. In that event, an informed course of action can be decided with a healthcare provider through appropriate precautions and frequent observations that may reduce the risk of cancer or help diagnose it early, when treatment is more beneficial. Awareness and prevention may reduce the risk of developing melanoma and other skin cancers. When spending time outdoors, limiting your exposure to UV rays is the most important way to lower the risk of developing skin cancer. This can be done by staying in the shade, wearing a hat, sunglasses, and protective clothing, and by using a broad-spectrum sunscreen lotion with SPF 30 or higher. Frequently performing self-skin checks to identify any new or abnormal moles can lead to an early diagnosis and increased chances of a successful treatment. When a change is noticed, informing a healthcare provider as soon as possible can be lifesaving. Raising awareness and educating society regarding the risk factors and warning signs of melanoma is the best tool to prevent and reduce the number of skin cancers.
PreSENTIA and ForeSENTIA cancer tests, offered by NIPD Genetics, can detect numerous genetic changes. PreSENTIA offers an extensive portfolio of 19 hereditary cancer test panels for identifying mutations with cancer susceptibility. ForeSENTIA offers an extensive portfolio of 7 cancer panels for wide coverage of genes implicated in specific cancer types. To learn more please visit www.nipd.com.
The content is intended only for educational purposes and should not be perceived as medical advice.
Compiled using information from:
-American Cancer Society. [https://www.cancer.org/cancer/melanoma-skin-cancer.html]
-Skin Cancer Foundation. [https://www.skincancer.org/skin-cancer-information/melanoma/melanoma-treatments/]
-NHS, Skin Cancer (melanoma). [https://www.nhs.uk/conditions/melanoma-skin-cancer/]
-World Cancer Research Fun, Skin cancer statistics. [https://www.wcrf.org/dietandcancer/skin-cancer-statistics/]
-National Foundation for Cancer Research, 9 Must-Know Facts About Sunscreen. [https://www.nfcr.org/blog/9-must-know-facts-about-sunscreen/]
-National Foundation for Cancer Research, Therapeutic Vaccines Showed Long-term Anti-Cancer Effects for Melanoma. [https://www.nfcr.org/blog/therapeutic-vaccines-showed-long-term-anti-cancer-effects-for-melanoma-2021-mw/]
-National Foundation for Cancer Research, Skin Cancer Awareness Month: Be Proactive, Reduce Your Risk. [https://www.nfcr.org/blog/skin-cancer-awareness-month-be-proactive-reduce-your-risk/]
-Centers for Disease Control and Prevention, Melanoma of the Skin Statistics. [https://gis.cdc.gov/Cancer/USCS/DataViz.html]
Up to 1 in 10 people with pancreatic cancer have a hereditary predisposition
Pancreatic cancer is the 15th most common cancer worldwide, but it has …Read More
Healthcare systems around the world should be encouraged to make polycystic ovary syndrome a priority in women’s health checks
Polycystic ovary syndrome (PCOS) affects 1 …Read More
Precision Medicine testing approach that optimizes cancer treatment
September 21, 2021, Nicosia, Cyprus: NIPD Genetics announces the launch of NeoThetis for therapy selection, the first …Read More
The history of vaccines dates back hundreds of years. Starting from variolation – the deliberate infection of an individual from material taken from an infected …Read More
NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.
At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.
NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:
NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:
Email address: firstname.lastname@example.org
Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus
Telephone number: + 357 22266888
We collect and process several types of personal information from and about users of our websites and of our products and services, including:
If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.
Your personal information is collected by NIPD Genetics for the following purposes:
To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.
This sensitive information described above is collected by NIPD Genetics for the following purposes:
Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.
If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.
NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.
NIPD Genetics may disclose your personal information in the good faith that such action is necessary:
Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.
You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.
Examples of Cookies we may use:
Session Cookies. We use Session Cookies to operate our websites.
Preference Cookies. We use Preference Cookies to remember your preferences and various settings.
Security Cookies. We use Security Cookies for security purposes.
Visitor behavior cookies. To understand how visitors use and navigate the websites
Keyword cookies. To understand how visitors discover the websites.
We may use third-party Service Providers to monitor and analyze the use of our websites.
Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.
For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page
We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.
These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.
We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.
NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:
You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.
Effective date: 18/06/2021Ok got it!